Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement
about
Influence of immunoglobulin isotype on therapeutic antibody functionPrinciples of antibody-mediated TNF receptor activationEngineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine.Blocking TWEAK-Fn14 interaction inhibits hematopoietic stem cell transplantation-induced intestinal cell death and reduces GVHD.Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo.Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.Therapeutic targeting of CD70 and CD27.Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB.Anti-FcγRIIB (CD32) Antibodies Differentially Modulate Murine FVIII-Specific Recall Response in vitro.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction.CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.Signaling by Antibodies: Recent Progress.Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.Translating Inhibitory Fc Receptor Biology into Novel Therapeutic Approaches.Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies.Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer TherapyFcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody.Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.The Use of Anti-CD40 mAb in Cancer.Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.
P2860
Q26772080-D9B31D0A-579A-4732-A608-ADD630DE4D6FQ26796270-BBA38599-FA44-4153-8B98-D915C3D95C06Q27678516-F71AE374-698C-4A40-B38A-0F97E2AF9CDFQ34978570-37F19977-0091-4E75-8950-A3EEA620551CQ35600313-7C104EF0-E108-43B8-AA42-E1DA4C62DA63Q35954775-C66497DB-BEE6-41EC-B246-5B5AA9FAF97EQ37353182-3F8C6449-A0A9-4A48-B0F8-FAC000D7AACBQ37563516-47611E1A-372A-4CBC-8FD9-0691EE9836C0Q38094625-D4A25935-C059-42F7-B716-85841A8AED29Q38615353-4599C46B-A979-4C0C-82A7-351B17B9BB9CQ38749841-002A3C9D-B90A-42F5-9129-896BE8DC618AQ38752906-EB9F5832-C02C-4FBC-968D-6CB2159231E9Q38754659-3FD6C4DA-B2E0-407B-9B34-F0F5C685C430Q38770814-625A978B-5AE7-4F49-903B-D27B4424ED59Q38782706-EFD02722-C6B6-404F-B455-D57C507C6DFAQ38931192-9779E617-6CC8-4CAD-B03D-93127644EE7DQ39028796-296F5319-3D7A-4EED-83D9-293C27CE768AQ39264890-45450754-2EF1-4B39-822A-CF03EEEF695AQ40560816-91AC1BED-1FD3-420A-8D12-75D883B0390FQ40762677-6595925A-9F3D-49F3-A6CD-A6C0832E9E18Q41855863-AA75B3E9-8D89-4D10-AD9E-B20181BDD1C2Q42280832-95DD6D84-0DC5-432E-B531-1BD4B30E8361Q42445183-91BE0048-6E57-43C0-BC3A-F61B60535F7CQ42584647-A0CBE437-32DD-4766-AE23-7EC0336306ECQ42660162-0DC38DFB-C8A8-4A84-B980-A7BE7C2C9D51Q49847008-F5846720-2C07-48F1-BBDC-E95368AEE04FQ52342639-EC632415-E193-4AEA-A264-1E2C4DEFC2CCQ53321210-88B4F507-DE6C-4C80-A49C-30F39D6FA45DQ55012569-7DE67483-4CB9-4CDD-84E7-AF6058B17078
P2860
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Apoptotic and antitumor activi ...... bitory Fcγ receptor engagement
@ast
Apoptotic and antitumor activi ...... bitory Fcγ receptor engagement
@en
type
label
Apoptotic and antitumor activi ...... bitory Fcγ receptor engagement
@ast
Apoptotic and antitumor activi ...... bitory Fcγ receptor engagement
@en
prefLabel
Apoptotic and antitumor activi ...... bitory Fcγ receptor engagement
@ast
Apoptotic and antitumor activi ...... bitory Fcγ receptor engagement
@en
P2860
P356
P1476
Apoptotic and antitumor activi ...... bitory Fcγ receptor engagement
@en
P2093
Jeffrey V Ravetch
P2860
P304
10966-10971
P356
10.1073/PNAS.1208698109
P407
P577
2012-06-20T00:00:00Z